Novavax Covid-19 vaccine receives Australian TGA approval for adolescents
The approval is based on findings from the paediatric expansion of the Phase III PREVENT-19 trial underway in the US.

The approval is based on findings from the paediatric expansion of the Phase III PREVENT-19 trial underway in the US.
The committee’s positive opinion is based on scientific data submitted by the company, including complete safety findings.
Pharmaceutical Technology lists five of the top tweets on infectious diseases in Q2 2022 based on data from GlobalData’s Pharmaceuticals…
The EC member states will now buy 1.25 million doses of VLA2001 this year after amending the previous purchase deal.
The tixagevimab and cilgavimab combination is anticipated to be made available in August.
The latest results show that current therapies that hinder all BET proteins are unlikely to be effective for Covid-19.
The companies will expedite the stockpiling, channel distribution and offer access to hospitals for the antibody therapy.
In Phase II/III KidCOVE trial, the vaccine offered a strong neutralising antibody response in children.
Thank you for subscribing to Pharmaceutical Technology